8-KMaterial AgreementsExhibits & Filings

AMGEN INC 8-K Report, Material Agreement (Oct 18, 2019)

Filed October 18, 2019For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on October 17, 2019, to report on an amendment to a material definitive agreement. Specifically, the company entered into Amendment No. 1 to the Asset Purchase Agreement (APA) on October 17, 2019. The material terms of the original APA, which was entered into on August 26, 2019, are detailed in a previous 8-K filing. This filing primarily serves to disclose the execution of this amendment. While the specific details of the amendment are not provided in this 8-K excerpt, it signifies a modification to the previously established asset purchase agreement with Celgene Corporation. Investors should refer to the original August 26, 2019, 8-K filing and the newly filed Amendment No. 1 (Exhibit 10.1) for a comprehensive understanding of the terms and implications of this agreement.

Key Highlights

  • 1Amgen Inc. entered into Amendment No. 1 to an Asset Purchase Agreement (APA) on October 17, 2019.
  • 2The amendment relates to a material definitive agreement, indicating a significant contractual change.
  • 3The original APA was entered into on August 25, 2019, with Celgene Corporation.
  • 4The material terms of the original APA were previously disclosed in an 8-K filing on August 26, 2019.
  • 5This 8-K filing (filed October 17, 2019) primarily serves to announce the execution of the amendment.
  • 6Exhibit 10.1 contains the full text of Amendment No. 1 to the APA.

Frequently Asked Questions

The main purpose of this 8-K filing is to report that Amgen Inc. entered into Amendment No. 1 to an Asset Purchase Agreement (APA) on October 17, 2019.

The other party to the Asset Purchase Agreement is Celgene Corporation.

The material terms of the original Asset Purchase Agreement were disclosed in Amgen's Current Report on Form 8-K filed on August 26, 2019. For the specific terms of the amendment, investors should refer to Exhibit 10.1 filed with this 8-K.

This specific 8-K filing announces the execution of Amendment No. 1 but does not detail the changes within the excerpt provided. Investors would need to review Exhibit 10.1, which contains the full text of the amendment, for those details.